Lee Schwartzberg
Expertise in
22
conditions

Dr. Lee Schwartzberg

Oncology
Office
75 Pringle Way Ste 801, 
Reno, NV 
Offers Telehealth
Expertise in
22
conditions
Office
75 Pringle Way Ste 801, 
Reno, NV 

Overview

Lee Schwartzberg is an Oncologist in Reno, Nevada. Dr. Schwartzberg is highly rated in 22 conditions, according to our data. His top areas of expertise are Breast Cancer, Agranulocytosis, Febrile Neutropenia, Paget Disease of the Breast, and Tissue Biopsy.

His clinical research consists of co-authoring 230 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in NV

Hospital Affiliations

Renown Regional Medical Center
Renown South Meadows Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
75 Pringle Way Ste 801, Reno, NV 89502
Other Locations
The West Clinic PLLC
7945 Wolf River Blvd, Germantown, TN 38138

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
Enrollment Status: Terminated
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Abemaciclib, Non-steroidal AI or steroidal AI or Fulvestrant
Study Phase: Phase 3
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Diagnostic test
Evaluation of a Mobile App to Promote Social Support for Oncology Patients
Evaluation of a Mobile App to Promote Social Support for Oncology Patients
Enrollment Status: Completed
Publish Date: December 18, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)
RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 9 Less Clinical Trials

230 Total Publications

Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.
Journal: Future oncology (London, England)
Published: December 15, 2025
Similar Doctors
Expertise in
41
conditions
Dr. Sowjanya Reganti
Hematology | Oncology
Expertise in
41
conditions
Dr. Sowjanya Reganti
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (157.7 miles away)
775-329-0222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sowjanya Reganti is a Hematologist and an Oncologist in Reno, Nevada. Dr. Reganti is highly rated in 41 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Reganti is currently accepting new patients.

Expertise in
59
conditions
Dr. Suresh V. Reddy
Hematology | Oncology
Expertise in
59
conditions
Dr. Suresh V. Reddy
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (157.7 miles away)
775-329-0222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suresh Reddy is a Hematologist and an Oncologist in Reno, Nevada. Dr. Reddy is highly rated in 59 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Reddy is currently accepting new patients.

Expertise in
70
conditions
Dr. Santhosh G. Ambika
Hematology | Oncology
Expertise in
70
conditions
Dr. Santhosh G. Ambika
Hematology | Oncology

Cancer Care Specialists

5423 Reno Corporate Drive, 
Reno, NV 
 (157.7 miles away)
775-329-0222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santhosh Ambika is a Hematologist and an Oncologist in Reno, Nevada. Dr. Ambika is highly rated in 70 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Follicular Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Ambika is currently accepting new patients.

Frequently Asked Questions about Dr. Lee Schwartzberg

How do I make an appointment with Dr. Lee Schwartzberg?

You can book an appointment with Dr. Lee Schwartzberg by calling their office at 775-982-2820. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lee Schwartzberg a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lee Schwartzberg is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lee Schwartzberg specialize in?

While Dr. Lee Schwartzberg is a Oncology, they have specific expertise in Breast Cancer, Agranulocytosis, and Febrile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Lee Schwartzberg participate in research or clinical trials?

Yes. Dr. Lee Schwartzberg has published 230 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Lee Schwartzberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lee Schwartzberg accept my insurance?

Dr. Lee Schwartzberg accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 775-982-2820 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schwartzberg's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile